Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Genetically modified micro-organism – cell – or virus
Reexamination Certificate
2006-09-12
2006-09-12
Wilson, Michael (Department: 1632)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Genetically modified micro-organism, cell, or virus
C424S093100, C424S093210, C514S04400A
Reexamination Certificate
active
07105156
ABSTRACT:
Disclosed are methods of controlling cell cycle progression by introducing into a cell to be controlled a composition selected from the group consisting of p56RBprotein, a fragment of the p56RBprotein, and the gene encoding p56RBprotein to alter the cell cycle progression while maintaining the viability of the cell. The p56RBprotein has been found to have the unexpected and surprising characteristic of being soluble in low concentrations of glycerol, thereby enhancing its value in pharmaceutical applications and the gene encoding p56RBwhen delivered to the hyperproliferating cell inhibits cellular proliferation.
REFERENCES:
patent: 4497796 (1985-02-01), Salser et al.
patent: 4736866 (1988-04-01), Leder et al.
patent: 4783313 (1988-11-01), Makari et al.
patent: 4803072 (1989-02-01), Dalton et al.
patent: 4942123 (1990-07-01), Lee et al.
patent: 5011773 (1991-04-01), Lee et al.
patent: 5496731 (1996-03-01), Xu et al.
patent: 5932210 (1999-08-01), Gregory et al.
patent: 6290949 (2001-09-01), French et al.
patent: 0259031 (1987-08-01), None
patent: WO89/06703 (1989-07-01), None
patent: WO90/05180 (1990-05-01), None
patent: WO91/09114 (1991-06-01), None
Orkin, S. et al. (1995), Report & Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy.
Mulligan, R. (1993). Science 260, 926-937.
Marshall, E (1995), Science 269, 1050-55.
Culver, K. (1994). Trende—Genins 10, 174-178.
Weinberg, R. (1995) Cell 81, 323-330.
Benlcuer, K. (1988). Biotechniques 6, 616-628.
Miller et al., Targeted vectors for gene therapy, 1995,FASEB J., vol. 9 pp. 190-199.
Deonarain, Ligand-targeted receptor-mediated vectors for gene delivery, 1998,Expert Opin. Ther. Pat., vol. 8 pp. 53-69.
Verma et al., Gene therapy-promises, problems and prospects, 1997, NATURE, vol. 389 pp. 239-242.
Crystal, Transfer of genes to humans: Early lessons and obstacles to success, 1995, SCIENCE, vol. 270, pp. 404-410.
Chang et al., Cystostatic gene therapy for vascular proliferative disorders with constitutively active form of the retinoblastoma gene product, 1995, SCIENCE, vol. 267 pp. 518-522.
Seltzer et al., Inhibition of vascular smooth muscle cell proliferation in vitro and in vivo by a replication-defective adenovirus encoding a non-phosphorylatable retinoblastoma gene product, 1994, CIRCULATION, vol. 90 pp. I-90 abstract Q475.
Meng et al., Tumor suppressor genes as targets for cancer gene therapy, 1999, Gene Therapy of Cancer, Chapter 1, pp. 3-20.
Vogelstein et al., The multistep nature of cancer, 1993, Trends in Genetics, vol. 9, pp. 138-141.
Huang et al., Suppression of the neoplastic phenotype by replacement of the RB gene in human cancer cells, 1988, SCIENCE, vol. 242, pp. 1563-1566.
Lemarchand et al., Adenovirus-mediated transfer of a recombinant human alpha1-antitrypsin cDNA to human endothelial cells, 1992, Proc. Natl. Acad. Sci. USA, vol. 89, pp. 6482-6486.
Huang et al., a cellular protein that competes with SV40 T antigen for binding to the retinoblastoma gene product, 1991, NATURE, vol. 350, pp. 160-162.
Angier, N., “Light Cast on a Darkling Gene.”DiscoverMar.:85-96 (1987).
Bender, et al., “Chromosomal Walking and Jumping to Isolate DNA from the Ace and rosy Loci and the Bithorax Complex inDrosophila melanogaster.”J. Mol. Biol.168:17-33 (1983).
Benedict, et al., “Nonrandom Chromosomal Changes in Untreated Retinoblastomas.”Cancer Genet. and Cytogenet. 10:311-333 (1983).
Benedict, et al., “Patient with 13 Chromosome Deletion Evidence that the Retinoblastoma Gene Is a Recessive Cancer Gene.”Science219:973-975 (1983).
Bignon, et al., “Expression of a retinoblastoma transgene results in dwarf mice.”Genes&Development7:1654-1662 (1993).
Bookstein, et al., “Human retinoblastoma susceptibility gene: Genomic organization and analysis of heterozygous intragenic deletion mutants.”Proceedings of the National Academy of Sciences85:2210-2214 (1988).
Bookstein, et al., “Suppression of Tumorigenicity of Human Prostate Carcinoma Cells by Replacing a Mutated RB Gene.”Science247:712-715 (1990).
Bowen, et al., “The detection of DNA-binding proteins by protein blotting.”Nucleic Acids Research8:1-20 (1980).
Buchkovich, et al., “The Retinoblastoma Protein Is Phosphorylated during Specific Phases of the Cell Cycle.”Cell58:1097-1105 (1989).
Capecchi, Mario R, “Altering the Genome by Homologous Recombination.”Science244:1288-1292 (1989).
Cavenee, et al., “Expression of recessive alleles by chromosomal mechanisms in retinoblastoma.”Nature305:779-783 (1983).
Cavenee, et al., “Isolation and Regional Localization of DNA Segments Revealing Polymorphic Loci from Human Chromosome 13.”Am. J. Hum. Genet.36:10-24 (1984).
Cepko, et al., “Construction and Applications of a Highly Transmissible Murine Retrovirus Shuttle Vector.”Cell37:1053-1062 (1984).
Chen, et al., “Phosphorylation of the Retinoblastoma Gene Product Is Modulated during the Cell Cycle and Cellular Differentiation.”Cell58:1193-1198 (1989).
Cooper, Geoffrey M. “Tumor Suppressor Genes.”Oncogenes, 121-139 (1990).
Cooper, J.A. and Whyte, Peter, “RB and the Cell Cycle: Entrance or Exit?” Cell 58:1009-1011 (1989).
Cordaro, J.C., “Transgenic Mice as Future Tools in Risk Assessment.”Risk Analysis9(2):157-168 (1989).
Cordon-Cardo, et al., “Altered Expression of the Retinoblastoma Gene Product: Prognostic Indicator in Bladder Cancer.”J. Natl. Cancer Inst.84(16):1251-1256 (1992).
DeCaprio, et al., “The Product of the Retinoblastoma Susceptibility Gene Has Properties of a Cell Cycle Regulatory Element.”Cell58:1085-1095 (1989).
DeCaprio, et al., “SV40 Large Tumor Antigen Forms a Specific Complex with the Product of the Retinoblastoma Susceptibility Gene.”Cell54:275-283 (1988).
Dixon, Richard A. and Nathans, Daniel, “Purification of Simian Virus 40 Large T Antigen by Immunoaffinity Chromatography.”Journal of Virology53:1001-1004 (1985).
Doerfler, W., “Expression of theAutographa californicaNuclear Polyhedrosia Virus Genome in Insect Cells: Homologous Viral and Heterologous Vertebrate Genes—The Baculovirus Vector System.”Current Topics in Microl. Immunol.131:51-68 (1986).
Donner, et al., “Nuclear localization and DNA binding of the transforming gene product of avian myelocytomatosis virus.”Nature296:262-266 (1982).
Dryja, et al., “Chromosome 13 Homozygosity in Osteosarcoma without Retinoblastoma.”Am. J. Hum Genet.38:59-66 (1986).
Dryja, et al., “Genetic Sequences That Predispose to Retinoblastoma and Osteosarcoma.”Symposium on Fundamental Cancer Research39:115-119 (1987).
Dryja, et al., “Molecular detection of deletions involving band q14 of chromosome 13 in retinoblastomas.”Proceedings of the National Academy of Sciences83:7391-7394 (1986).
Dyson, et al., “The Human Papilloma Virus-16 E7 Oncoprotein Is Able to Bind to the Retinoblastoma Gene Product.” Science 243:934-937 (1989).
Edwards, et al., “Purification and Characterization of a Functionally Homogenous 60-kDa Species of the Retinoblastoma Gene Product”The Journal of Biological Chemistry267(12):7971-7974 (1992).
Eliyahu, et al., “Wild-type p53 can inhibit oncogene-mediated focus formation.”Proceedings of the National Academy of Sciences86:8763-8767 (1989).
Friedmann, Theodore, “Gene Therapy of Cancer through Restoration of Tumor-Suppressor Functions?”Cancer20:1810-1817 (1992).
Friedmann, Theodore, “Progress Toward Human Gene Therapy.”Science244:1275-1281 (1989).
Friend, et al., “Deletions of a DNA sequence in retinoblastomas and mesenchymal tumors: Organization of the sequence and its encoded protein.”Proceedings of the National Academy of Sciences84:9059-9063 (1987).
Friend, et al., “A human DNA segment with properties of the gene that predisposes t
Goodrich David
Gregory Richard J.
Lee Eva
Lee Wen-Hwa
Maneval Daniel C.
Canji Inc.
The Regents of the University of California
Townsend and Townsend / and Crew LLP
Wilson Michael
LandOfFree
Method of using an adenoviral vector encoding a... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of using an adenoviral vector encoding a..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of using an adenoviral vector encoding a... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3619899